10x Genomics, Inc. (NASDAQ:TXG) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Arias - Stifel Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Salem Salem - Barclays Tejas Savant - Morgan Stanley John Sourbeer - UBS Mason Carrico - Stephens Michael Ryskin - Bank of Amer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name ...

10X Genomics, Inc. (NASDAQ:TXG) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Cassie Corneau - Manager, IR and Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Justin McAnear - CFO Conference Call Participants Patrick Donnelly - Citigroup Daniel Arias - Stifel, Nicolaus & Company Kyle Boucher - TD Cowen Michael Ryskin - Bank of America Merrill Lynch Tejas Savant - Morgan Stanley Matthew Larew - William Blair & Company Mason Carrico - Stephens Inc. Tianqi Hang - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Re ...

10x Genomics, Inc. (NASDAQ:TXG) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Cassie Corneau – Head-Investor Relations & Strategic Finance Serge Saxonov – Chief Executive Officer and Co-founder Justin McAnear – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Dan Brennan – Cowen Tejas Savant – Morgan Stanley Patrick Donnelly – Citi Matthew Sykes – Goldman Sachs Kyle Mikson – Canaccord Julia Qin – J.P. Morgan Mason Carrico – Stephens Michael Ryskin – Bank ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2022 Earnings Conference Call February 15, 2023 4:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Dan Brennan - Cowen Dan Arias - Stifel Tejas Savant - Morgan Stanley Patrick Donnelly - Citigroup Julia Qin - J.P. Morgan Kyle Mikson - Canaccord Genuity Matt Larew - William Blair Michael Ryskin - Bank of Americ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specif ...

10x Genomics, Inc. (NASDAQ:TXG) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Dan Arias - Stifel Patrick Donnelly - Citi Kyle Mikson - Canaccord Genuity Dan Brennan - Cowen Julia Qin - JPMorgan Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Operato ...

Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-5614458 (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPOR ...